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ABSTRACT 
The mechanisms behind Alzheimer’s disease (AD) are largely unknown. The 
disease is to a large extent hereditary, and the best pathophysiological 
correlate to the severity of the symptoms is loss of synapses. 
The general aim of this thesis was to examine the hypothesis that AD is 
primarily a synaptic disease – with an emphasis on complement-mediated 
elimination of synapses. 
Animal models of AD have shown that long-term potentiation (LTP) of 
synapses is inhibited by beta amyloid (Aβ). LTP is considered to be a 
physiological correlate to learning and memory, and Aβ is a peptide that 
constitute the extracellular plaques that characterise AD. The Aβ induced 
inhibition of LTP has been shown to be dependent on the receptor for 
advanced glycation end products (RAGE). In the present thesis I present 
results that suggest an association of a functional single nucleotide 
polymorphism (SNP) in the gene encoding RAGE with diagnosis of AD. 
Thus linking the synapse related pathophysiology observed in animal models, 
to human patients with AD. 
During development, synapses in the retinogeniculate system and the 
sensorimotor cortex of mice are eliminated in a complement mediated 
manner. Since AD pathology primarily affects the hippocampus, we sought 
to investigate whether the complement system mediates elimination of 
hippocampal synapses as well. Indeed, by use of complement component 3 
 (C3) deficient mice, electrophysiological, histological, molecular and 
behavioural methods, we obtained results that suggest this for a fact. 
Considering the importance of synapse loss in AD we decided to measure the 
levels of the complement proteins C3, complement component 4 (C4), 
complement factor B (CFB) and complement receptor 1 (CR1) in 
cerebrospinal fluid (CSF) from patients with various degrees of AD. The 
results showed a trend towards increased complement levels in AD patients. 
This association, however, was too weak to be of diagnostic value. 
Nevertheless it supports the notion of complement involvement in AD. 
Next we hypothesised that genetic variation in genes encoding complement 
proteins could potentially be associated with diagnosis of AD. Therefore, we 
investigated SNPs in the complement genes CR1, C3, CFB, and the second 
complement component (C2). Although no such associations were found, we 
did, however, find an association of C2/CFB SNPs with measures of 
cognitive function (MMSE) and neuronal damage (tau) in AD patients, thus 
lending further support for the hypothesis of complement mediated synaptic 
elimination in AD. 
I conclude that several lines of evidence suggest that AD might very well be 
the result of aberrant complement regulation, with improper synaptic 
elimination as a consequence. Precise knowledge about the mechanisms 
underlying AD is of great value to research into accurate diagnostic methods 
and treatments, thus, further research on the subject of synapse elimination in 
AD is warranted. 
Keywords: Alzheimer’s disease, Synapse, Complement, RAGE, Biomarker, 
Genetics, SNP. 
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SAMMANFATTNING PÅ SVENSKA 
Mekanismerna bakom Alzheimers sjukdom är i stort sett okända, men det 
som bäst förklarar symptomens svårighetsgrad är antalet synapser. Med 
avstamp i detta förhållande är den grundläggande frågeställningen i denna 
avhandling huruvida Alzheimers sjukdom primärt är en synapssjukdom. 
Djurförsök har visat att långtidspotentiering (LTP) av synapser hämmas av 
amyloid β (Aβ), det protein som till största delen utgör de amyloida plack 
som karaktäriserar sjukdomen patologiskt. Detta är mycket intressant 
eftersom LTP anses vara det cellulära substratet för minne och inlärning. 
Hämningen har visats vara beroende av proteinet RAGE; därför undersökte 
vi huruvida en variant av genen för detta protein var associerad med 
Alzheimers sjukdom. En sådan association fanns och detta tolkar vi som att 
de observationer av RAGE-beroende LTP-hämning som gjorts i djurmodeller 
av Alzheimers sjukdom skulle kunna vara relevanta för sjukdomens 
utveckling även hos människor. 
Eftersom förlust av synapser karaktäriserar Alzheimers sjukdom undersökte 
vi fenomenet synapseliminering i hippocampus (den del av hjärnan som först 
drabbas av Alzheimerspatologi). Här kunde vi med olika elektrofysiologiska 
metoder visa att möss som saknar genen för komplementkomponent 3 (C3) 
har en störd synapseliminering, vilket innebär att komplementsystemet skulle 
kunna vara involverat i Alzheimers sjukdom. Därför mätte vi halterna av 
komplementproteinerna C3, C4 och CR1 i ryggmärgsvätska från personer 
med olika grad av Alzheimers sjukdom och resultaten visade på signifikanta 
skillnader i halterna av dessa. 
För att ytterligare stärka upp hypotesen undersökte vi varianter av 
komplementgenerna C2, C3, CFB och CR1 hos Alzheimerspatienter och 
friska kontrollpersoner. Trots betydande stöd i litteraturen för att dessa gener 
skulle vara associerade med Alzheimers sjukdom fann vi inga associationer 
mellan dessa genvarianter och Alzheimersdiagnos. Vi fann däremot att en 
variant av C2 och CFB var associerad med Alzheimerspatienternas kognitiva 
förmåga och mängden hyperfosforylerat tau (ett protein som är kopplat till 
Alzhemers sjukdom och hjärnskada). 
Sammanfattningsvis presenterar jag i denna avhandling ett visst stöd för 
hypotesen att den grundläggande problematiken vid Alzheimers sjukdom 
utgörs av synapspatologi och att den kan vara associerad med förändringar i 
RAGE- och komplementsystemet. 
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1 INTRODUCTION 
1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) was first described by Alois Alzheimer in 1906 
(Maurer et al. 1997). It is the most common form of dementia, and it is 
characterized by a progressive decline in cognitive ability. This can be 
attributed to the progressive loss of synapses and neurons seen in patients. At 
least two forms of AD are recognized; early onset familial AD (FAD), where 
a single mutation in a key AD gene causes AD in an autosomal dominant, 
fully penetrant manner, and sporadic AD (SAD) where several risk factors, 
both genetic and environmental, are thought to contribute to the disease.  
1.1.1 Diagnosis 
Clinically, the disease is foremost characterized by amnesia - beginning as 
anterograde amnesia, and as the disease progresses this is followed by a 
retrograde amnesia (Salmon and Bondi 2009). Other psychiatric symptoms 
are common, and include emotional and attention deficits (Salmon and Bondi 
2009). Several tests are used to assess cognitive function when trying to 
determine diagnosis. One of the simplest and most frequently used is mini 
mental state examination (MMSE) (Tombaugh and McIntyre 1992; Folstein 
et al. 1975). 
Traditionally, AD has been a post mortem diagnosis. Aside from progressive 
cognitive deterioration, the patient also has to show some specific 
pathological changes. These hallmarks of the disease were described as 
plaques and tangles by Alois Alzheimer over a century ago. In the eighties 
the plaques were shown to consist mainly of the 42 amino acid long β-
amyloid peptide (Aβ42) (Glenner and Wong 1984; Masters et al. 1985; Wong 
et al. 1985), whereas the tangles were shown to be made up of hyper-
phosphorylated tau protein (Grundke-Iqbal et al. 1986). These two molecules 
now constitute the core cerebrospinal fluid (CSF) biomarkers for AD 
(Blennow et al. 2010). Diagnosis is chiefly based on clinical assessments, but 
in recently revised diagnostic criteria biomarkers have entered as important 
adjuncts (http://www.alzheimersanddementia.org/content/ncg). Other 
methods utilised include different brain imaging techniques, such as magnetic 
resonance imaging (MRI).  
In the present thesis AD subjects fulfilled the DSM-IIIR criteria of dementia 
(Spitzer et al. 1987) and were either pathologically confirmed or fulfilled the 
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criteria of probable AD defined by NINCDS-ADRDA (McKhann et al. 1984) 
which was further supported by CSF biomarkers. 
MCI is defined as not normal but not demented. Cognitive impairment can be 
reported by the patient him- or herself, but is preferably also confirmed by an 
informant, and in objective neuropsychological tests. An alternative criterion 
is evidence of cognitive decline over time. Otherwise the patient should be 
able to lead an ordinary life with only minimal impairment in complex 
instrumental functions (Winblad et al. 2004). Around 50% of MCI patients 
eventually develop AD, whereas the remaining 50% have benign cognitive 
impairment or suffer from other neurodegenerative conditions.  
Although there is no cure for AD, a correct diagnosis is important to exclude 
other diagnoses for which treatment might be available. It is also important in 
order to provide the patient and relatives with correct information and a 
reasonable prognosis so they know what to expect of the future, enabling 
them to make arrangements and plans in good time. Lastly, efforts in making 
accurate early diagnoses will hopefully pay off when treatments become 
available. 
1.1.2 Epidemiology 
In 2011 AD had a prevalence of about 34 million cases worldwide (Barnes 
and Yaffe 2011). The incidence is approximately 1% and increases 
exponentially with age (Reitz et al. 2011). Due to increased life expectancies, 
the prevalence has been estimated to triple over the next 40 years (Barnes and 
Yaffe 2011). The suffering and economic impact cannot be overstated. 
Age is the major risk factor for AD. FAD has a marked earlier onset than 
SAD; typically it starts in the late 40’s or early 50’s and has an absolute 
genetic aetiology. Although the present thesis only concerns the more 
common SAD, it is important to note that FAD and SAD are clinically and 
neuropathologically similar, and since all known FAD mutations are located 
in genes involved in Aβ processing, a common conclusion is that Aβ should 
play a central role in AD. 
SAD, in contrast to FAD, has a later onset, and a more complicated 
aetiology, where several risk factors are thought to contribute. Twin studies 
have shown that as much as 60-80% of the risk is of hereditary origin (Gatz 
et al. 2006). The only confirmed susceptibility gene is the ε4 allele of the 
apolipoprotein E gene (APOE ε4) (Corder et al. 1993; Kurz et al. 1996; 
Poirier et al. 1993). Although APOE ε4 has been suggested to account for 20-
30% of the risk (Reitz et al. 2011), it is neither necessary nor sufficient for 
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disease (Myers et al. 1996). This leaves a lot to explain, and probably several 
small effect susceptibility genes work together in a complex manner to cause 
the disease. Other risk factors are female sex, and vascular disease and its 
associated risk factors (Reitz et al. 2011; Bendlin et al. 2010). 
1.2 Synapses 
The brain is the organ responsible for our mental experiences and abilities. It 
achieves this through the workings of a complex network of neurons and glial 
cells. The human brain houses approximately 100 billion neurons, these are 
interconnected via approximately 100 trillion synapses (Squire 2008). 
1.2.1 Synaptic transmission 
Synapses transfer, process and store information; accordingly, the synapse 
should be regarded as the ultimate functional unit in the central nervous 
system (CNS). The vast majority of synapses in the brain are glutamatergic 
(Megias et al. 2001), meaning that the transmitter substance released from the 
presynaptic bouton in order to convey a signal from the presynaptic cell to 
the postsynaptic cell, is glutamate. There also exist GABAergic synapses, 
these are typically inhibitory; further there is a class of modulatory synapses 
which utilize a vast range of transmitters, modulating neural activity via 
volume transmission, the lack of specificity is why these structures should 
not be considered as synapses. 
The basis for neural transmission is excitability. When a neuron is excited 
enough, it fires an action potential along its axon, thereby increasing the 
probability of exciting the neurons it is connected to. Excitability is regulated 
in part by the neuron itself, this is called intrinsic excitability, and in part by 
the sum of synaptic input it receives from other neurons, extrinsic 
excitability. Extrinsic excitability is positively regulated by excitatory 
synaptic input, and negatively regulated by inhibitory synaptic input – the 
balance between excitation and inhibition is of utmost importance in neuronal 
networks. 
When a great enough number of excitatory synapses are activated, either 
spatially or temporally, onto a given neuron, it will fire an action potential 
that will spread along its axon, reaching all of the presynaptic terminals 
where it will give rise to a Ca2+ transient, and through this momentarily 
increase the probability of transmitter release, if transmitter is released, the 
transmitter substance will diffuse over the synaptic cleft and bind to receptor 
molecules in the postsynaptic membrane. These receptors are coupled to ion 
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channels, and in the case of an excitatory synapse, this opening will lead to a 
transient depolarisation of the postsynaptic membrane, known as an 
excitatory postsynaptic potential (EPSP). If this EPSP is accompanied by 
several other EPSPs in the postsynaptic neuron, this neuron will in turn 
convey the signal to the neurons it is connected to. However, this is not a 
linear process; it depends on the efficacy of each synapse, if the signal will be 
transferred to the postsynaptic neuron. 
Synaptic efficacy is determined by three parameters, n*p*q, where n is the 
number of synapses or release sites, p is the release probability of a single 
synaptic vesicle, and q is the quantal size, which is the magnitude of the 
postsynaptic response to release of a single synaptic vesicle (Korn and Faber 
1991). 
1.2.2 Synaptic plasticity 
Plasticity is a fundamental aspect of neural networks - neither intrinsic 
excitability nor synaptic efficacy is fixed. These parameters are constantly 
changing in an activity-dependent manner. During development these 
phenomena ensure that the neuronal network is efficiently wired; in the more 
mature brain, however, they provide the brain with the necessary means to 
adapt to a changing environment, and to store information, thus enabling 
anticipation of the future (Kandel and O'Dell 1992). 
One of the more thoroughly investigated forms of plasticity is long-term 
potentiation (LTP) of the glutamate synapse in the hippocampus (Kerchner 
and Nicoll 2008). LTP is commonly regarded as the neurophysiological 
substrate for learning and memory. Although there are good reasons to 
believe that this is actually true, it has not been shown that LTP is neither 
necessary nor sufficient for learning and memory (Martin et al. 2000). The 
concept was invented by Donald Hebb in the monumental book The 
organisation of behaviour (Hebb 1949). Briefly, he suggested that the 
connections between neurons that are active simultaneously, should be 
strengthened, thus providing a physiological substrate for lasting association. 
More than two decades later this hypothetical phenomenon was indeed 
observed by use of extracellular field recordings in rabbits (Bliss and Lomo 
1973), and spurred new interest in the search for the engram. A puzzling 
question that was left unanswered was how two neurons could “know” that 
they were active simultaneously. The putative coincidence detector was 
finally shown to be the N-methyl-D-aspartate receptor (NMDAR) by 
Wigström and Gustafsson in 1986 (Wigstrom and Gustafsson 1986). The 
NMDAR is both voltage- and ligand-gated, meaning that in order for the 
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channel to open, it requires glutamate, which is released from the presynaptic 
terminal, in conjunction with postsynaptic depolarisation which is needed to 
relieve the channel from of a magnesium ion that blocks the channel at 
resting membrane potential. Hence, if the NMDAR is located in the 
postsynaptic membrane, the channel only opens when the two neurons that 
are connected via the synapse, are simultaneously active. Moreover, the 
NMDAR is permeable to calcium ions, and these work as intracellular second 
messengers, signalling that the synapse should be reinforced. There has been 
some debate as to whether the strengthening is of a pre- or postsynaptic 
locus, and the answer seems to be both, mainly depending on which synapse 
the investigator is examining. In the hippocampal CA3/CA1 synapse, most 
researchers agree that LTP is expressed as an increased number of glutamate 
receptors of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPAR) type in the postsynaptic membrane. 
LTP is balanced by the process of long-term depression (LTD). The function 
and mechanisms of LTD is less well understood, but it appears as if at least 
some forms of LTD are dependent on the NMDAR. This is a puzzling 
feature, but it is generally believed that LTP requires a robust and temporally 
precise activation of the NMDARs, whereas an intermediate or scanty 
activation leads to LTD (Malenka and Bear 2004). 
Other kinds of synaptic plasticity include various forms of short-term 
plasticity and homeostatic plasticity. Short-term plasticity is usually of a 
presynaptic nature, affecting release probability in various ways (Zucker and 
Regehr 2002). Probably these phenomena aid in the processing of 
information, rather than storage of it. Paired pulse plasticity is perhaps the 
most familiar form of short-term plasticity; it is frequently used to investigate 
release probability, and the common conception is that residual calcium after 
the first pulse increases the release probability of the second pulse and 
therefore giving rise to a greater postsynaptic response. This occurs in 
synapses with a low release probability and is called facilitation; when the 
second pulse generates a smaller postsynaptic response, the phenomenon is 
called depression, and this occurs in synapses with a high initial release 
probability. 
The aforementioned forms of synaptic plasticity affects specific synapses to 
enable processing and storage of information. Homeostatic plasticity on the 
other hand, is thought to globally affect synaptic transmission, thereby 
keeping the relative differences in synaptic efficacy intact (Turrigiano 2008; 
Vitureira et al. 2011). 
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1.2.3 Synaptogenesis and synaptic elimination 
The generation of functional neuronal networks during brain development is 
based on an extensive iteration of synaptogenesis (the formation of new 
synapses) and synaptic elimination (Hua and Smith 2004). Since generation 
and elimination of synapses is relatively fast, occurring on a scale of minutes 
to hours, and extensive generation/elimination of synapses is thought to 
continue up until puberty (Hua and Smith 2004; Bourgeois et al. 1994; 
Bourgeois and Rakic 1993; Zecevic and Rakic 1991), the evolving neuronal 
networks are expected to have the possibility of testing the functionality of a 
vast number of combinations. In this scenario, a disturbance of synaptic 
elimination is expected to decrease the functionality of the synaptic networks, 
since it would force the brain to keep the synaptic connections that form, 
regardless of functionality. Accordingly, faulty regulation of synapse 
numbers has been implicated in the aetiology of several psychiatric disorders 
(Penzes et al. 2011). Schizophrenia and autism spectrum disorders probably 
have aetiologies of a developmental origin, whereas AD could be the result of 
a faulty reactivated developmental synaptic elimination (Penzes et al. 2011; 
Wasling et al. 2009). 
Synaptogenesis, which would be the positive regulation of n, has been quite 
extensively studied (Christopherson et al. 2005; Eroglu et al. 2009; 
Kucukdereli et al. 2011; Terauchi et al. 2010). However, as in most 
biological systems, the parameter n is also under negative regulation. 
Although this process is far less well understood, it has been shown that 
synaptogenesis is limited by proteins in the Nogo receptor family (Wills et al. 
2012), and recent efforts have begun to unravel the mechanisms of synaptic 
elimination in the cerebrum. 
There are good reasons to believe that LTP and LTD are involved in synaptic 
elimination. Since the functional synapses are those that participate in 
synchronous firing, and this circumstance also leads to potentiation of them, 
it should be expected that LTP protects from elimination, perhaps indirectly, 
by reducing the probability of LTD (Peineau et al. 2007) – which on the other 
hand, is often the consequence of asynchronous firing, thus, affecting 
synapses with little value in the network. In accordance, it has been shown 
that LTD can induce elimination of synapses (Nagerl et al. 2004; Shinoda et 
al. 2005; Kamikubo et al. 2006; Bastrikova et al. 2008; Becker et al. 2008). 
Interestingly, it was recently shown that freezing behaviour after fear 
conditioning correlated with spine elimination in the frontal association 
cortex of mice (Lai et al. 2012). Excitatory synapses are often localized to 
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small dendritic protrusions called spines, and the Lai et al. (2012) study 
suggests that elimination of synapses are directly involved in learning; 
alternatively that impaired elimination leads to an inefficient neuronal 
network, or perhaps most likely, both. Either way, the study strongly 
implicates the process of synaptic elimination in the formation of memories. 
The details of the elimination process are largely unknown, but it has been 
shown that the complement system is somehow involved (Stevens et al. 
2007; Paolicelli et al. 2011; Chu et al. 2010; Schafer et al. 2012). 
The complement system is probably better known for its role in the innate 
immune response. It consists of more than thirty proteins, mainly zymogens, 
which when activated, aggregate and catalyse the formation of active 
complement components, forming a cascade that ultimately works to 
eliminate foreign objects such as pathogens (Sarma and Ward 2011). This is 
done either by opsonisation and attraction of macrophages, or by formation 
of the membrane attack complex which forms a pore in the infected cell 
membrane and thereby induces direct cell lysis. Exactly how complement 
proteins work to eliminate synapses is still not known. However, elimination 
is most likely initiated by complement component 1q (C1q) (Stevens et al. 
2007), the starting point of the classical complement cascade. 
Studies of transgenic mice, lacking the genes encoding C1q and complement 
component 3 (C3) revealed that the complement system is involved in 
eliminating retinogeniculate connections (Stevens et al. 2007) and synapses 
in the sensorimotor cortex (Chu et al. 2010). A role for microglia has been 
implicated by showing how inhibition of microglial motility resulted in 
defective synapse elimination in the hippocampus (Paolicelli et al. 2011). In 
addition, Paolicelli and colleagues (2011) also reported that they found the 
postsynaptic density protein PSD95 in microglia, suggesting that these cells 
engulf synapses. A recent study corroborates this by presenting evidence for 
that retinogeniculate synapses are actually engulfed by microglia, at least the 
presynaptic portion (Schafer et al. 2012). It was further shown that this was 
dependent on the complement component 3 receptor (C3R) and C3 signalling 
(Schafer et al. 2012). 
Aside from the complement system the proteins semaphorin 3A/F and 5B, 
and ephrin have also been implicated in synapse elimination (Bagri et al. 
2003; O'Connor et al. 2009; Tada and Sheng 2006; Fu et al. 2007). Another 
group of proteins that have been implicated are the neuronal pentraxins 
(Bjartmar et al. 2006). This is interesting since some of these molecules are 
situated in synapses (Gerrow and El-Husseini 2007) and can bind C1q 
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(Sarma and Ward 2011), thus providing a potential platform for the classical 
complement cascade. 
1.3 Synaptic pathophysiology in AD 
The major clinical hallmark of AD is amnesia, and as already mentioned, Aβ 
seems to play a central role in AD pathogenesis. Interestingly, the pathology 
usually debuts in the hippocampal formation in the temporal lobe of the 
brain; an anatomic structure that is intimately associated with learning and 
memory (Squire and Wixted 2011). Since the cellular substrate for learning 
and memory is thought to be LTP, Aβ might in some way inhibit LTP. 
Indeed, quite a few animal studies have shown this for a fact (Shankar et al. 
2008; Townsend et al. 2007; Walsh et al. 2002; Klyubin et al. 2008; 
Knobloch et al. 2007; Kamenetz et al. 2003; Chang et al. 2006; Chapman et 
al. 1999). The mechanism by which Aβ inhibits LTP is not clear however, 
but a number of pathways have been implicated through various experimental 
studies. The phosphatases: calcineurin (Chen et al. 2002), PP1 (Knobloch et 
al. 2007), and striatal enriched phosphatase (Chin et al. 2004); the kinases: 
p38 MAPK (Wang et al. 2004), cdk5 (Wang et al. 2004), Erk/MAPK 
(Townsend et al. 2007), Akt/PKB (Townsend et al. 2007), GSK3β (Koh et al. 
2008; Takashima et al. 1996), PKA/CREB (Vitolo et al. 2002), and CAMKII 
(Townsend et al. 2007; Zhao et al. 2004); the insulin receptor (Townsend et 
al. 2007), the receptor for advanced glycation end products (RAGE) (Arancio 
et al. 2004; Origlia et al. 2009; Origlia et al. 2008), glutamate uptake (Li et al. 
2009) and the prion protein (Kessels et al. 2010; Barry et al. 2011) have all 
been shown to be implicated in the Aβ-induced LTP inhibition. 
There are also some studies suggesting that the threshold for LTD is lower in 
animal models of AD (Hsieh et al. 2006; Li et al. 2009; Cheng et al. 2009). 
This is very interesting since it has also been shown that LTD can lead to 
synapse elimination (Nagerl et al. 2004; Shinoda et al. 2005; Kamikubo et al. 
2006; Bastrikova et al. 2008; Becker et al. 2008) and loss of synapses is the 
pathophysiological feature of AD brains that best correlates with the severity 
of the symptoms (Scheff and Price 2003; DeKosky and Scheff 1990; Terry et 
al. 1991). 
Other studies have shown that application of Aβ to a slice of hippocampal 
tissue induces synapse elimination in the slice (Qu et al. 2011; Shankar et al. 
2007; Shrestha et al. 2006). Knockout mice, lacking APP have been shown to 
have more synapses than wild type (WT) mice (Priller et al. 2006); 
conversely, transgenic mice overexpressing human APP have fewer synapses 
than WT mice (Koffie et al. 2009; Smith et al. 2009; Qu et al. 2011). 
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Recent animal studies have shown that synaptic elimination is dependent on 
the complement system. Interestingly, knockout of C1q in transgenic mice 
expressing human APP with FAD mutations produces a minor 
neuropathological phenotype (Fonseca et al. 2004). In line with this 
mechanism of elimination, investigation of post mortem brain tissue from AD 
patients have shown increased levels of complement mRNA (Yasojima et al. 
1999), this finding has been further supported by studies showing increased 
levels of complement proteins in the CSF from AD patients (Finehout et al. 
2005; Wang et al. 2011). In addition, it has been shown that the genes 
encoding complement receptor 1 (CR1) and complement factor H (CFH) are 
associated with AD diagnosis (Harold et al. 2009; Lambert et al. 2009; Naj et 
al. 2011; Seshadri et al. 2010; Zetterberg et al. 2008). 
In conclusion, these findings warrant a closer investigation of the 
involvement of the complement system and synaptic elimination in AD. 
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2 AIM 
2.1 The general aim 
The general aim of this thesis was to examine the hypothesis that AD is 
primarily a synaptic disease – with an emphasis on complement-mediated 
elimination of synapses. 
2.2 The specific aims 
I. To examine if genetic variation in the gene encoding the 
RAGE receptor is associated with AD. 
 
II. To investigate if the complement system is involved in 
elimination of synapses in the hippocampus of mice. 
 
III. To measure the levels of C3, C4, and CR1 in CSF from 
patients with MCI, probable AD, MCI patients who later 
developed probable AD, and compare them with the 
levels in healthy controls, with the purpose of evaluating 
these proteins as potential biomarkers for AD, and to 
gain evidence for complement involvement in AD. 
 
IV. To evaluate the complement genes CR1, C3, C2 and 
CFB as possible susceptibility genes for AD. 
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3 METHODOLOGICAL 
CONSIDERATIONS 
3.1 Subjects 
The subjects of the different studies were chosen to best provide an answer to 
the questions posed in the specific aims. In general I have preferred to work 
with human subjects for both scientific and ethical reasons - mice do not 
become demented nor can they provide consent. 
3.1.1 Patients 
For details on diagnostic procedures and other information on the patients 
please refer to the different papers. The patients in our studies were 
diagnosed with MCI, AD or other neurodegenerative conditions using 
standardised clinical methods and test batteries performed by psychiatrists 
and psychologists at specialised memory clinics. Controls were cognitively 
normal according to these tests. A clinical diagnosis of AD is not perfect and 
it has been estimated that 10-16% misdiagnoses occur in relation to 
neuropathology (Brunnstrom and Englund 2009; Galasko et al. 1994; 
Victoroff et al. 1995), which often is considered the gold standard diagnostic 
method. Biomarkers for AD neuropathology, e.g., CSF levels of Aβ42 and 
tau proteins, may help to increase the diagnostic accuracy compared with 
clinical criteria (Blennow et al. 2010), but studies showing this for a fact are 
still lacking. Clinical AD diagnoses in papers I and IV were confirmed either 
by a typical CSF tau and Aβ biomarker profile or at autopsy according to the 
neuropathological CERAD criteria for definitive AD (Mirra et al. 1991). 
3.1.2 Mice 
To study the role of the complement system in elimination of synapses in the 
hippocampus, mice deficient in C3 were used (Pekna et al. 1998). These mice 
do not lack the whole gene, but the critical exon 24, which renders the gene 
product incomplete and thus non-functioning (Pekna et al. 1998). To ensure 
almost identical genetic backgrounds between WT controls (C57Bl/6) and C3 
knockout mice (C3 KO), the C3 KO mice were backcrossed for 13 
generations. 
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3.2 Genotyping 
Genotyping of single nucleotide polymorphisms (SNPs) was made by use of 
TaqMan allelic discrimination, a polymerase chain reaction (PCR)-based 
assay. PCR is a method of DNA amplification, based on the molecular 
mechanisms of DNA replication (Mullis and Faloona 1987). A sample of 
DNA is heated to approximately 95ºC to make the two DNA strands separate, 
subsequently the temperature is lowered to 50-60ºC in order to enable 
hybridisation of two oligonucleotides (predesigned DNA molecules that bind 
to a specific region of the genome) that flank the desired sequence of the 
sample DNA and work as primers for the DNA polymerase. Then the 
temperature is raised again, to 72ºC, and the heat-stable DNA polymerase, 
Taq polymerase, will commence with the work of replicating the DNA 
sequence singled out by the primers. Thus, the sequence of interest is doubled 
for each cycle. 
The TaqMan allelic discrimination is accomplished by cleavage of a 
fluorescent dye from the TaqMan probe by the exonuclease activity of the 
Taq polymerase as it replicates the SNP-containing sequence. Two probes are 
used in the reaction, one for each allele, thus enabling identification of 
heterozygotes and both kinds of homozygotes (Livak et al. 1995). 
PCR is easy in theory but difficult to optimize in practice. In the present 
thesis all genotyping experiments were performed by certified lab technicians 
specialised in molecular genetics, using commercially available kits. 
TaqMan allelic discrimination is an excellent method for genotyping a 
limited number ?? SNP? since no post-PCR handling is required, thus,  
minimizing the risk of contamination. 
3.3 Electrophysiology 
Electrophysiology was chosen as the primary method for quantifying 
synapses for the reason that the assessment only concerns functional 
synapses. 
3.3.1 Hippocampal slice preparation 
The hippocampus (fig. 1 in paper II) has been extensively studied in the past 
40 years. It is a brain formation of fundamental importance for learning and 
memory, it is easily recognised, and the cell layers are arranged in a laminar 
way which makes the structure very suitable to use when recording 
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extracellular field potentials (Andersen 2007). In addition, the hippocampus 
is the site in the brain where AD pathology usually first appears, making it 
highly relevant to study considering the aims of this thesis. 
The acute hippocampal slice preparation was chosen for most of the 
electrophysiological studies because it leaves much of the circuitry intact 
while still allowing for pharmacological manipulation. 
Figure 1. A typical fEPSP. The first transient deflection seen in this picture (1.) is the 
shock artefact generated by the electrical stimulation. The second, smaller deflection 
(2.) is the fibre volley which corresponds to the action potentials evoked by the 
stimulation. The action potentials will subsequently promote release of transmitter in 
the presynaptic terminals, leading to the third larger deflection (3.) which is the 
postsynaptic potential. 
3.3.2 Extracellular field recordings 
The field EPSP (fEPSP) recorded in a hippocampal slice is generated by the 
actions of hundreds of neurones, and subsequently tens of thousands of 
synapses. The pyramidal neurons in CA1 are organised in one layer with their 
apical dendrites projecting perpendicular from that layer. The currents 
generated by synaptic activity in these dendrites will flow intracellularly in 
the same general direction towards the soma where they will exit and flow 
back along the apical dendrites in the extracellular space, thereby generating 
an electrical field. Experimentally, such field potentials can easily be evoked 
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by electrical stimulation of the axons of the pyramidal cells in CA3, called 
the Shaffer collaterals. The recorded fEPSP will reflect the events of its 
making (fig. 1) and constitutes a great sample of synapses.  
The strength in this approach is also its weakness; while many synapses are 
sampled and thus provide a robust measurement, it is impossible to 
differentiate between different types of synapses. The relevance of such a 
differentiation in the present thesis is, however, very limited. 
Input/output measurements 
Input/output measurements are an excellent and very straight forward way to 
measure synaptic efficacy. The size of the fibre volley corresponds to the 
number of axons stimulated (Andersen et al. 1978), whereas the fEPSP is the 
response from the activated population of synapses. By testing different 
stimulation intensities and plotting the magnitude of the fEPSP against that of 
the volley a measure of synaptic efficacy per axon can be obtained. 
The strength of this method is its simplicity; however, this is also its 
weakness, since we cannot know which quantal parameters (i.e. n, p or q) are 
changing. 
Paired pulse recordings 
This type of stimulation paradigm, where two synaptic responses are elicited 
in close succession, is commonly used to detect changes in the quantal 
parameter p (Branco and Staras 2009). The size of the second pulse in 
relation to the first pulse is described by the paired pulse ratio (PPR), and 
calculated as the second pulse divided by the first pulse. When the PPR is 
larger than 1, the plasticity is called facilitation and taken as a sign of a low 
initial p (Zucker and Regehr 2002). 
Interpretation of PPR data should be made with caution, however; changes in 
release probability as a consequence of changes in vesicle pool size, results in 
no or very modest changes in PPR (Hanse and Gustafsson 2001; 
Abrahamsson et al. 2005). Moreover, if postsynaptic changes (i.e. changes in 
q) occur in a subpopulation of either high- or low-release probability 
synapses, the PPR would change, thus falsely hint on a change in p. 
Nevertheless, paired pulse recordings are simple, and an excellent way to 
probe for changes in release probability. 
MK- 801 experiments 
MK-801 is an irreversible open channel blocker, specific for the NMDAR. 
This can be utilised to estimate release probability in an almost direct manner 
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since the rate of decay of the NMDAR EPSP magnitude is dependent on the 
presynaptic release probability (Hessler et al. 1993; Wasling et al. 2004). 
When a synaptic vesicle is released, the opposing NMDARs open; the 
resulting EPSP is recorded, but since MK-801 is present, these NMDARs are 
irreversibly blocked, which means that the synaptic NMDARs are turned off 
in a release-dependent way. A limitation of this method is that the decay also 
depends on the open probability of the individual NMDARs. In this study we 
have no information on this, and cannot exclude that there is a difference 
between the studied groups. There is, however, no reason to believe that 
knockout of exon 24 in C3 should affect the open probability of the 
NMDARs. 
Burst recordings 
Single pulses are very common in electrophysiological experiments; 
however, in the hippocampus in vivo, neurons often fire bursts of action 
potentials. This is why it can be of importance to investigate how some 
physiological phenomena respond to burst stimulation. A problem is that the 
EPSPs become distorted by back propagating action potentials, to a large 
extent this problem can be overcome by measuring the initial slope of the 
EPSP, instead of measuring the amplitude or perhaps the area under the 
whole burst response. 
3.3.3 Whole cell patch clamp recordings 
The patch-clamp technique was invented by Sakmann and Neher in 1976 
(Neher and Sakmann 1976). Briefly, the technique is based on establishing a 
high resistance seal between a glass pipette containing an electrode, and a 
cell, thus enabling control of the cell membrane voltage or current. By setting 
the voltage over the membrane, or clamping the membrane potential as it is 
normally put, currents flowing over the cell membrane can be measured. In 
the present work, this has been utilised in the simplest possible way by 
measuring miniature synaptic currents. The major advantage of whole cell 
recordings is that they enable a dissection of the quantal parameters. 
In the present investigations, field recordings were done when possible, but 
to estimate quantal size, patch clamp whole cell recordings were necessary. 
Aside from being more technically demanding, whole cell experiments also 
carry the disadvantage of being further invasive by disrupting the 
intracellular milieu; this have been shown to greatly affect the possibility of 
inducing LTP (Malinow and Tsien 1990), but it has most likely not affected 
the results presented here. 
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3.4 Behavioural testing 
To investigate if the C3 KO mice displayed an abnormal learning ability, we 
assessed their aptitude for contextual and cued fear conditioning. Two 
paradigms of fear conditioning (brief delay and trace), were tested. 
Training was carried out in two different settings (differing in visual 
appearance and smell), one setting was safe (no shocks delivered) and one 
setting was unsafe (shocks delivered). The shocks were paired with tones. In 
the brief delay paradigm the tone and shock were temporally close, whereas 
they were more separated in the trace paradigm. 
The basic concept is that contextual fear conditioning (using the cues that are 
present in the conditioning box throughout the entire conditioning session) 
tests hippocampal-dependent learning and memory, while cued fear 
conditioning (using the cue that is explicitly paired with the shock, the tone in 
this case) tests hippocampal-independent/amygdala-dependent learning and 
memory. Animals with hippocampal lesions can still learn cued fear 
conditioning, but are impaired on contextual fear conditioning (Otto and 
Poon 2006). Cued fear conditioning becomes hippocampal-dependent when 
there is a longer delay between the end of the tone and the beginning of the 
shock. Hence, memory of the tone-shock association using the brief delay 
procedure reflects hippocampal-independent memory, while memory of the 
contextual cue-shock association in either procedure and memory of the tone-
shock association in the trace delay procedure reflect hippocampal-dependent 
memory. 
3.5 Antibody- based assays 
The biggest issue with antibody-based assays is the specificity of the 
antibodies used. In the present work, all antibodies used were commercially 
available and specificity was assured by the manufacturers. No additional 
validation was performed. 
3.5.1 Immunohistochemistry 
In order to corroborate the electrophysiological findings, 
immunohistochemical detection of synapses was performed. Thin sections of 
hippocampal tissue were made. These were incubated with an antibody 
specific for the presynaptic protein VGLUT1, the primary antibody. This was 
followed by incubation with a fluorescently labelled antibody against the 
primary antibody, thus providing amplification of the signal, while 
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maintaining the specificity of it, and enabling visual detection of presynaptic 
terminals. Images were then taken by use of confocal microscopy. 
Because of the small size and vast amount of synaptic puncta, an automated 
high content analysis of the images was performed (Dragunow 2008) by an 
investigator blind to the genotype of the sections. 
3.5.2 Western blot 
Western blot is a commonly used method to detect a specific protein in a 
sample. Relative difference in amounts of the protein can also be estimated. 
Briefly, proteins were extracted from freshly dissected hippocampal tissue, 
and total protein concentrations were measured. Subsequently, equal amounts 
of protein were added to a gel, and under the influence of an electric field the 
proteins run down the gel, distributed according to size. Then the proteins 
were transferred to a membrane that was incubated with a primary antibody, 
followed by incubation with an enzyme linked secondary antibody which 
catalyses a reaction producing a chemiluminescent signal which is quantified 
and taken as a measure of the protein. 
The drawback with western blot is that it does not provide any absolute 
concentrations, but when the question posed only regards relative differences, 
western blot is a sufficient method. 
3.5.3 ELISA 
ELISA is an abbreviation for enzyme-linked immunosorbent assay, and that 
is exactly what it is. An antibody specific for the protein of interest is 
attached to a surface (e.g. well, plate, or beads), the sample containing the 
protein to be analysed is added to the surface, and as a consequence of the 
specific antibodies attached to this, the protein will be adsorbed to the surface 
(immunosorbed). This is followed by washing, thus leaving only the protein 
of interest on the surface, then an enzyme linked or biotinylated antibody is 
added. In the case of a biotin-conjugated antibody, a secondary streptavidin-
conjugated enzyme is added. Thus the protein to be analysed is sandwiched 
between two specific antibodies and each such complex is linked to an 
enzyme. In the final step, a substrate for the enzyme is added, and the 
reaction is quantified using a set of standard samples containing known 
concentrations of the analyte. 
An ELISA can be more sensitive than a western blot, and allows for 
measurement of absolute concentrations. This is necessary for analysis of all 
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chemical biomarkers where concentrations are indicative as opposed to mere 
presence. 
3.6 qPCR 
Real time quantitative PCR (qPCR) is a PCR-based technique for quantifying 
nucleic acids. In the present thesis it was combined with reverse transcription 
PCR, where mRNA is transcribed to its corresponding complementary DNA 
(cDNA). The cDNA is then amplified by PCR. Instead of quantifying the 
PCR product after the reaction, the PCR product is measured during the 
reaction in real time. Here this was accomplished by the presence of a 
molecule that fluoresce when it binds to double stranded DNA (SYBR 
GREEN), thus when the single-stranded DNA recombines in the PCR cycle. 
Quantification is based on comparison with a standard curve, and to correct 
for variation between different samples, the signal from the gene of interest is 
normalised to that of a stably expressed reference gene. 
3.7 Statistics 
Most science is based on comparisons, e.g. different experimental settings, 
study groups or changes over time. The common way of dealing with the 
analysis is to evaluate two hypotheses – the null hypothesis, according to 
which the difference between the groups is zero, and the alternative 
hypothesis, according to which there is a difference in the material. Normal 
variation in combination with chance can result in seemingly substantial 
differences between different samples; therefore it is important to estimate 
the element of chance. This is usually done by calculating a p-value which is 
the probability of the observation occurring while the null hypothesis is true. 
Differences are denoted as significant if the p-value fall under a stipulated 
cut-off level, usually set to 0.05. Thus, if the p-value is lower than 0.05, the 
null hypothesis should be refuted, and the alternative hypothesis accepted. 
If the null hypothesis is rejected though no true difference actually exists, a 
Type I error has been made (the probability for this to occur is the stipulated 
significance level). Conversely, if the null hypothesis is accepted while a true 
difference actually exists, a Type II error has been made. To avoid Type II 
errors it is necessary to have a large enough sample size in respect to the 
variability in the variable investigated. The necessary sample size can be 
estimated by a power calculation. Statistical power is the probability of 
detecting a true difference, if it exists, hence of not making a Type II error. 
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Hypothesis testing can be made by use of a vast number of more or less 
complicated statistical methods. Statistical software enables non-statisticians 
to perform the tests without knowledge about the actual calculations. 
However, this comes with the risk of performing wrong tests and making 
faulty conclusions. This possible limitation has been restricted by seeking 
advice from relevant experts in the field. 
Since falsely significant differences are identified by chance according to the 
chosen significance level, and this applies to each test being made, it is often 
advisable to correct the p-value for multiple testing when several tests are 
made. The easiest way to do this is by use of the Bonferroni method, where 
the p-values are simply multiplied by the number of tests that were 
performed. However, these methods are often very conservative, as a 
consequence real differences might be discarded. 
Alleles in a randomly mating population without any evolutionary selection 
pressures will occur in stably fixed proportions. This is called Hardy-
Weinberg equilibrium. In the gene association studies, Hardy-Weinberg 
equilibrium was assessed by comparing theoretical genotype distributions, 
calculated on the basis of observed allele frequencies, with observed 
genotype frequencies using χ2-test. This ensures detection of genotyping 
errors that could otherwise lead to false associations. However, Hardy-
Weinberg disequilibrium might also reflect natural selection as a 
consequence of an actual association. 
In gene association studies, risk estimations for carriers of the susceptibility 
gene are relevant, not only to estimate the risk, but also as a measure of the 
effect size of the studied gene. Since most diseases are uncommon, a 
randomly selected cohort or a selection of carriers and non-carriers, are very 
impractical because of the large sample size needed in such approaches. The 
common way is instead to use a case-control design. However, this means 
that a proper risk ratio cannot be calculated, since the study population was 
not randomly selected from the whole population. Instead an odds ratio (OR) 
has to be used. The OR represents the risk of an outcome and is interpreted in 
relation to 1 which means that the subject under study has no effect on risk. 
An OR of more than 1 means an increased risk, whereas an OR of a number 
less than 1 should be interpreted as protective. 
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4 SUMMARY OF RESULTS 
4.1 Association of RAGE with AD diagnosis 
In an attempt to provide a link between recent animal studies showing that 
the RAGE receptor mediates the LTP inhibiting effect of Aβ, and actual 
human AD patients, we investigated the genetic variability in the gene 
encoding RAGE (somewhat confusingly the gene is named advanced 
glycation end-products receptor (AGER)), and it’s relation to AD. 
While working on this project, a study (Li et al. 2010a) on the very same 
subject was published. This group showed an association of the functional 
82S SNP with AD in a Chinese cohort. In the field of genetics this is actually 
a good thing, since independent replications in separate populations are 
needed. In contrast to the study by Li et al. (2010) all AD cases in our 
material were neurochemically confirmed and of European origin (further 
demographics are given in Table 1, paper I). 
Our study investigated some additional SNPs in AGER (Table 2, paper I), 
although none of these were associated with AD, the 82S allele was 
associated with an increased risk of AD (Pc=0.04, OR=2.0, 95% CI 1.2–3.4) 
(Table 3, paper I). There was no genetic interaction between AGER 82S and 
APOE ε4 in producing increased risk of AD (p=0.21) (Table 4, paper I), and 
none of the AGER SNPs showed association with Aβ42, T-tau, Ptau181 or 
MMSE scores. 
RAGE may affect both production and accumulation of Aβ in the brain 
(Chaney et al. 2005; Cho et al. 2009; Deane et al. 2003). Since the 82S 
variant of RAGE has an increased ligand-binding affinity (Hofmann et al. 
2002; Osawa et al. 2007) this could lead to increased signalling, which in 
turn, would accelerate APP-processing through BACE1 (since BACE1 has 
been shown to be positively regulated by RAGE (Cho et al. 2009)), and 
thereby increase Aβ production. An increased transport of peripheral Aβ into 
the brain would be expected as well, since RAGE has been shown to 
transport Aβ across the blood-brain barrier into the brain (Deane et al. 2003). 
However, we found no association between G82S genotype and Aβ levels. 
Another possibility is that the 82S variant may be more effective in mediating 
the LTP-inhibiting effect of Aβ (Arancio et al. 2004; Origlia et al. 2009; 
Origlia et al. 2008), a hypothesis that remains to be tested. 
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In conclusion, the present results, together with those from Li et al. (2010), 
suggest that AGER is a susceptibility gene for AD. 
4.2 Complement mediated synapse 
elimination in the hippocampus 
The complement system has been shown to be involved in elimination of 
retino geniculate synapses (Stevens et al. 2007) and synapses in the 
sensorimotor cortex (Chu et al. 2010) of mice. 
Considering that the first brain region to be affected in AD is the 
hippocampus, and that loss of synapses is perhaps the most relevant feature 
of the disease; investigation of the mechanisms of synapse elimination in the 
hippocampus is highly warranted. 
Thus we decided to investigate if the number of synapses is altered in mice 
lacking C3. The hypothesis was that these mice should have an increased 
number of synapses as a result of impaired synaptic elimination. 
An increased number of synapses should lead to an increased synaptic 
efficacy, when measured as the average synaptic response to a given number 
of stimulated axons. Surprisingly, the input/output measurements showed no 
difference between C3 KO and WT animals (Fig. 1, paper II). However, there 
was an increased PPR, indicating lower release probability in the C3 KO 
mice (Fig. 2, paper II). According to the formula for synaptic efficacy, n*p*q, 
a decreased release probability could potentially mask an increased synapse 
number. In order to ascertain the decreased release probability in the C3 KO 
mice, we recorded NMDAR EPSPs in the presence of MK-801. The resulting 
MK-curves showed that the release probability was indeed lowered (Fig. 3, 
paper II), thus supporting the original hypothesis that C3 KO mice have an 
increased number of synapses. 
This conclusion assumes that the quantal size remain unchanged. To test this, 
we made whole cell patch clamp recordings of miniature EPSCs. Since no 
difference in the size of the AMPAR EPSCs was observed (Fig. 4, paper II), 
we conclude that quantal size is not changed in C3 KO mice. In conjunction 
with a decreased release probability and unaltered input/output, the only 
sensible conclusion is that the C3-deficient mice must have an increased 
number of synapses. 
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This conclusion gained further support when we analysed the result of the 
burst stimulations. C3 KO mice displayed an increased synaptic response to 
burst-stimulations (Fig. 5, paper II), probably due to the normalising effect on 
release probability of the short-term plasticity induced by the burst. 
To corroborate the electrophysiological findings, we made 
immunohistochemical stainings of VGLUT1 in thin sections of hippocampal 
tissue from WT and C3 KO mice. Again surprised, we found that C3 KO 
mice had a lower density and smaller puncta of VGUT1 staining (Fig. 6, 
paper II), thus implying fewer synapses. An explanation for this result that 
would still fit together with the previous results, is, that in the C3 KO mice, 
synapses are more numerous, but smaller, so small that they creep under the 
detection level for immunohistochemistry. This rational comes with the 
prediction that the VGLUT1 protein levels in C3 KO mice should not be 
lower than in WT mice. Indeed, western blot and qPCR experiments showed 
that VGLUT1 expression was not different between C3 KO and WT mice, 
thus supporting the notion of more numerous but smaller synapses. In further 
support of this notion, it has been shown that mice lacking C1q, a protein 
found upstream of C3 in the classical complement cascade, in fact, have 
smaller synaptic boutons (Chu et al. 2010). 
Considering the importance of proper synapse elimination during 
development, C3 KO mice should display some learning disabilities. We 
confirmed this prediction by subjecting the animals to fear conditioning, 
showing that the C3 KO mice were blessed with an impaired memory for the 
foot shocks when the learning paradigm was hippocampus-dependent (Fig. 7, 
paper II). Interestingly, this opens for the possibility that synaptic elimination 
in the amygdala is not impaired by the lack of C3. 
In the last experiment of this study, we explored the possibility of an 
increased propensity for epileptiform activity in the brains of the C3 KO 
animals. Such an effect was seen in the previous study of C1q deficient mice 
(Chu et al. 2010) and could possibly be explained by the increased burst 
response reported in the present study. This notion is further supported by the 
fact that inhibitory GABAergic synapses do not seem to be eliminated in a 
complement-dependent manner (Chu et al. 2010). Therefore we recorded 
spontaneous activity in vivo in C3 KO and WT mice. We did, however, not 
observe any spontaneous seizures in the C3 KO mice (Fig. 8, paper II). 
In conclusion, these results implicate the complement system in the 
elimination of glutamate synapses in the hippocampus. They also suggest that 
the increased neuronal activity, an expected consequence of deficient 
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elimination and too many glutamate synapses, is partially compensated by 
reduced release probability, possibly via homeostatic plasticity. 
4.3 Complement levels in AD CSF 
Previous reports have shown that post mortem brain tissue from AD patients 
have increased levels of complement mRNA (Yasojima et al. 1999), and that 
AD CSF has increased levels of a certain isoform of C4b (Finehout et al. 
2005), C3 and factor H (Wang et al. 2011). Since the complement system 
seems to be involved in AD we evaluated the complement proteins, C3, C4 
and CR1 as potential CSF biomarkers for AD. 
C3 and C4 CSF levels were significantly higher in AD patients as compared 
to stable MCI patients (Table 1, and Fig. 1, paper III). Since the core 
biomarker patterns were similar between the control and stable MCI groups, 
and the MCI-AD and AD groups (Table 1, paper III), these were merged into 
a control/stable MCI group and an MCI-AD/AD group (Fig. 2, paper III). 
Statistical comparison of these two groups showed that the CR1 levels were 
significantly increased in the MCI-AD/AD group. C3 and C4 levels were not 
significantly different between the groups, but there was a trend towards 
higher C3 levels in the MCI-AD/ AD group (p = 0.068). 
To evaluate if the levels of C3, C4, or CR1 could be of diagnostic utility, 
receiver operating characteristic (ROC) curves were created for the different 
analytes. The core biomarkers T-tau, P-tau and Aβ42 could differentiate AD 
from controls with an area under the curve (AUC) of 0.96. When we added 
the complement proteins to this model, the AUC did not improve (Fig. 3, 
paper III). The variable importance in the projection (VIP) plots show the 
contributions of the different analytes to the model (Fig. 3, paper III). 
Although C3 and CR1 contributed to some extent, the magnitude was too 
small to be of clinical use. 
In addition to the primary analyses described above, we also investigated 
potential correlations between the different variables in the two merged 
groups (Table 2, paper III). The results showed that the levels of the 
complement proteins correlated with age and albumin ratio, an indicator of 
the blood-brain barrier function. Correlations were also seen between age, 
MMSE and albumin ratio. 
The correlation between complement levels and age has been reported in a 
previous study (Wang et al. 2011) and is somewhat unsettling considering the 
significant differences in age seen between the diagnostic groups in the 
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present study. However, the correlations of complement factors with age 
were not straight-forward. When examining correlations in the four 
subgroups separately, the correlations remained in controls and stable MCI 
patients, but disappeared in the AD subgroups, in spite of a large age span in 
those groups as well (Table 1, paper III). 
As expected, T-tau and P-tau levels were correlated in both groups. T-tau and 
P-tau were also correlated with age, Aβ42 and CR1 in the non-demented 
subjects. In AD patients, on the other hand, we observed a weak correlation 
between MMSE and Aβ42, MMSE and C4. 
In conclusion, the results of this study speak for complement involvement in 
the disease process occurring in patients with AD. None of the complement 
proteins C3, C4 and CR1 are, however, suitable as CSF biomarkers for 
clinical use. 
4.4 Complement gene SNPs in AD 
Clearly the genes of the complement system are interesting as candidate 
susceptibility genes for AD. CR1 and CFH have been implicated by previous 
studies (Harold et al. 2009; Lambert et al. 2009; Naj et al. 2011; Seshadri et 
al. 2010; Zetterberg et al. 2008; Ferrari et al. 2012; Hu et al. 2011). For the 
present gene association study, we selected genes that had previously been 
found associated with the neurodegenerative disease age-related macular 
degeneration (AMD) which in turn is epidemiologically linked to AD 
(Kaarniranta et al. 2011; Kirby et al. 2010). These genes were: C2, C3, and 
the gene encoding complement factor B (CFB). We also included CR1, since 
this gene has been associated with AD in several genome wide association 
studies (Harold et al. 2009; Lambert et al. 2009; Naj et al. 2011; Seshadri et 
al. 2010; Ferrari et al. 2012; Hu et al. 2011). 
No significant associations between the investigated SNPs and risk of AD 
were detected in our material (Table 3, paper IV). C2/CFB, (these two genes 
are tightly linked, and therefore inherited together) however, was associated 
with MMSE and T-tau in AD subjects; since the ORs are in the same 
direction as in previous studies on AMD (Sun et al. 2012) and the overlaps of 
the confidence intervals are substantial, it is quite possible that we failed to 
detect an actual association in this study. The same rational goes for the CR1 
replication. Meta-analysis of the SNP investigated here ends up with an 
OR=1.17 (www.alzgene.org) and is well within our estimated CI=(0.84 – 
1.37), thus our result supports rather than refutes the previously found 
associations. 
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In conclusion, the study failed to detect any associations of the selected 
complement SNPs and AD diagnosis. An association of the C2/CFB SNPs 
with T-tau levels and MMSE was found. These two parameters reflect the 
seriousness of the symptoms, and the association lends some support to the 
hypothesis of aberrant complement regulation in AD. 
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5 DISCUSSION 
In the present thesis I have explored some predictions of the hypothesis that 
AD is primarily a synaptic disorder. I have shown that a variant of the gene 
encoding the RAGE protein, which has been linked to synaptic dysfunction 
in animal models of AD, is associated with AD diagnosis. This study was 
followed by animal experiments in which the mechanisms of synaptic 
elimination in the hippocampus were investigated. Consistent with the results 
from previous studies in other brain areas, we found that synapses were 
eliminated in a complement mediated manner. This finding led us to explore 
certain neurochemical and genetic aspects of the complement system in 
patients with AD. The investigations showed a trend towards increased 
complement levels in AD CSF, and an association of C2/CFB variants with 
MMSE and tau levels in AD patients. 
In  the  following section  I  will  present  a  general  discussion ?? the 
pathogenesis and pathophysiology of AD. I will present a possible sequence 
of events that lead to AD, and discuss the results presented in my thesis in 
this hypothetical context. Finally, I will give my view on the ultimate reasons 
as to why people develop AD. 
5.1 The events leading to AD – a proposed 
model 
The common conception is that in AD, Aβ kills neurons. This is in principal 
correct, but several crucial steps in the process have been overlooked. 
Without doubt Aβ as well as tau are involved in AD. However, it is the 
number of synapses that best predict the severity of the dementia (DeKosky 
and Scheff 1990; Scheff and Price 2003; Terry et al. 1991). This comes as no 
surprise since synapses constitute the physical locus of memory storage. 
Lastly, AD is associated with a loss of neurons; this is, however, occurring in 
the later stages of the disease. 
5.1.1 It all starts with Aβ 
In FAD, the disease causing mutations all affect Aβ processing, either by 
favouring the more toxic 42 amino acid long variant, or by simply promoting 
production, with increased amounts as a consequence. In SAD, however, no 
such linear relationship exists. A multitude of risk factors, foremost genetic 
ones, are thought to cause the disease. Aside from ageing, APOE ε4 is the 
most prominent risk factor, and is known to be involved in Aβ clearance. 
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Perhaps compromised Aβ clearance is an initial culprit in SAD, followed by 
positive feedback loops, including RAGE, which will increase the production 
of Aβ when the scales tip over. 
5.1.2 Altered synaptic plasticity by Aβ 
Aβ inhibits LTP (Chang et al. 2006; Chapman et al. 1999; Kamenetz et al. 
2003; Klyubin et al. 2008; Knobloch et al. 2007; Shankar et al. 2008; 
Townsend et al. 2007; Walsh et al. 2002) and promotes LTD (Cheng et al. 
2009; Hsieh et al. 2006; Li et al. 2009). Several mechanisms have been 
proposed (Pozueta et al. 2012); of particular interest is a study showing that 
Aβ blocks glutamate uptake, thereby altering the induction thresholds for 
LTP and LTD, such that LTD is promoted on the expense of LTP (Li et al. 
2009). 
“What about tau?” some would ask. Tau is most certainly involved in AD 
pathogenesis (Hardy et al. 1998). No FAD-mutations are found in the gene 
encoding tau, however. Mutations do exist in tau, and causes dementing 
disorders such as frontotemporal dementia with Parkinsonism, this is, 
however, not associated with any Aβ pathology (Hardy and Selkoe 2002). 
Thus, it seems that in AD, Aβ is the causative agent, and that tau follows. 
Nevertheless, tau has been shown to be necessary for Aβ to inhibit LTP 
(Shipton et al. 2011) suggesting that Aβ is sufficient to initiate the pathologic 
cascade, but also that tau is necessary for its continuing rampage. 
A possible reason for the shift towards LTD could be an increased tonic 
NMDAR signalling since it has been shown that increasing the extracellular 
concentration of glutamate by blocking the glutamate uptake promotes LTD 
(Li et al. 2009; Yang et al. 2005). Additional findings pointing towards 
dysregulation of NMDARs in AD are those that have implicated the prion 
protein in Aβ pathophysiology (Stys et al. 2012; You et al. 2012; Parkin et al. 
2007; Griffiths et al. 2011). The prion protein regulates NMDAR 
desensitisation, and it has been shown that Aβ perturb this function of the 
prion protein, thus increasing the tonic activity of these receptors. This could 
potentially explain the findings of Aβ-induced excitotoxicity as well as the 
shift towards LTD and eventually apoptosis. 
5.1.3 Synapses are marked for destruction 
A possible link between LTD and elimination of synapses is a family of 
proteins called neuronal pentraxins (NP). These have been shown to be 
necessary for LTD in the hippocampus (Cho et al. 2008) and serve as binding 
sites for C1q (Perry and O'Connor 2008). Moreover, the levels of certain NPs 
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are increased in FAD CSF (Ringman et al. 2012). NP1 and NP2 (a.k.a. 
NARP) are secreted molecules that bind to, and cluster AMPARs. NP 
receptor (NPR) is a transmembrane protein that binds to AMPAR and NP1 
and NP2, thereby potentially anchoring AMPARs in the synaptic cleft. 
Stimulation of LTD (which would be increased by Aβ) also stimulates the 
enzyme tumor necrosis factor-alpha converting enzyme (TACE) to cleave the 
transmembrane domain of NPR, thus releasing it from the membrane (Cho et 
al. 2008). This event is associated with endocytosis of AMPAR and LTD 
(Cho et al. 2008). One can speculate that the released AMPAR-NP complex, 
act as an initiation point for the complement cascade when it moves outside 
the synaptic cleft. The complement proteins that would then bind to the 
AMPAR-NP complex could be of various origins. The main source of 
complement proteins in the body is the liver. A compromised blood-brain 
barrier can give peripheral complement access to the brain. This could be of 
pathological relevance, and it is interesting to note that Aβ-RAGE interaction 
can disrupt the blood-brain barrier (Kook et al. 2012). This pathway is not 
necessary, however, since complement is also produced in the brain. In the 
brain, complement components are secreted by both glia and neurons, mainly 
during development, but also in the adult brain in response to disease or 
trauma (Veerhuis et al. 2011; Stephan et al. 2012). Interestingly, Aβ can 
modulate complement activation (Wang et al. 2009), and knockout of C1q in 
a mouse model of AD reduced the decrease in synapse markers and 
activation of glia, otherwise observed in this model (Fonseca et al. 2004). 
5.1.4 Engulfment of synapses by microglia 
Several scenarios could follow once complement has marked a synapse. The 
complement cascade might reach its final stage in forming the membrane 
attack complex with subsequent lysis of the synapse as a consequence. 
Another possibility would be that the complement molecules act as a 
phagocytosis signal, attracting microglia that would respond by engulfing the 
synapse. Microglia have been implicated in the events of synaptic elimination 
by impairing their motility, and the observation of synaptic proteins in 
microglial endosomes (Paolicelli et al. 2011). Since hindering microglial 
motility impairs synaptic elimination, their role is conceivably beyond merely 
engulfing debris from cell-autonomous elimination. Therefore it seems more 
likely that complement marks synapses for elimination, and that this process 
is carried out in a most direct manner by phagocytosing microglia. 
5.1.5 Neuronal death 
An interesting consequence of fewer synapses is that it means less LTP, 
which aside from impaired learning abilities, also would lead to a decrease of 
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trophic factors to the cell (Hardingham and Bading 2010). Moreover, LTD is 
dependent on the apoptosis protein caspase-3 (Li et al. 2010b). It is 
conceivable that excessive LTD in the absence of LTP drives the neuron to 
apoptosis. In this respect it is interesting to note that overexpression of NP1 
increases the levels of activated caspase-3, the number of apoptotic cells in 
neuronal cultures (Abad et al. 2006) and that caspase-3 is increased in 
synaptosomes from AD brains compared to controls (Louneva et al. 2008). In 
addition, NP1 knockdown rescues these cells from Aβ induced toxicity 
(Abad et al. 2006). Moreover, post-mortem analyses of AD brains have 
shown that NP1 is associated with senile plaques and the synaptic protein 
SNAP-25 (Abad et al. 2006). 
5.1.6 Summary of the model 
To sum up, Aβ inhibits LTP and promotes LTD. This leads to cleavage of 
NPR, which enables AMPARs with associated NPs to escape the synaptic 
cleft, as they get overrun by complement binding to the NPs they attract 
microglia that engulf the synapse. The declining numbers of non-plastic 
synapses manifest as anterograde amnesia in the patient; decreasing synapse 
numbers and extensive LTD ultimately leads to accumulating apoptosis 
promoting factors and the subsequent death of neurons, manifesting as 
retrograde amnesia, and in the end, death of the patient. The model should be 
regarded as a working hypothesis, and is in need of rigorous testing. Outlined 
below is a discussion on how the results presented in this thesis render some 
support for some of the steps in the model. 
5.2 The present results in relation to the 
model 
RAGE has been implicated in the production of Aβ (Cho et al. 2009), as well 
as the transport of Aβ from the periphery to the brain over the blood brain 
barrier (Deane et al. 2003). Thus, the 82S variant of the RAGE receptor, 
which has an increased ligand binding affinity (Hofmann et al. 2002; Osawa 
et al. 2007), could lead to increased levels of Aβ. Although we did not 
observe any associations of AGER genotypes with Aβ levels, it is possible 
that such an association is visible only in the early stages of the disease, since 
high affinity would be most relevant in a context of low ligand concentration. 
Moreover, RAGE has been shown to mediate the Aβ-inhibition of LTP 
(Arancio et al. 2004; Origlia et al. 2009; Origlia et al. 2008), and to activate 
microglia (Bianchi et al. 2010). Aβ levels, LTP-inhibition, and activation of 
microglia are all important features of the proposed model, and by linking the 
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82S allele of AGER to AD, we have provided circumstantial evidence in 
support of the model. 
Complement mediated synaptic elimination is a key feature of the proposed 
model. Our results suggest that synapses in the hippocampus are eliminated 
through the actions of the complement system. This is a basic requirement for 
the model to hold up, since AD pathology primarily affects the hippocampus. 
These results were obtained in animal experiments; mice, do not become 
demented, however, and these results are in need of confirmation in humans. 
If true, however, a prediction that follows is that CSF complement levels 
would be altered in AD as a result of on-going synapse elimination in the 
hippocampus. Therefore, we investigated the levels of complement proteins 
in CSF from AD patients. Our results revealed a trend towards higher levels 
of complement in CSF from AD subjects, thus, supporting the model by 
suggesting increased complement activation in patients diagnosed with AD. 
In light of the previous findings linking aberrant complement regulation to 
AD, we hypothesised that some SNPs in genes encoding complement 
proteins could be associated with AD diagnosis. The selected SNPs did, 
however, not show any associations with diagnosis of AD. An association 
would have had to be regarded as support for the model, but the fact that we 
did not find any associations do not really speak against it. Moreover, the 
results were likely a consequence of an overestimated effect size on our 
behalf, to detect the differences with a satisfactory precision, a larger sample 
size would have been needed. We did, however, find an association of 
C2/CFB genotype with MMSE and t-tau in AD patients. This is interesting 
since CFB is a part in the alternative pathway of the complement cascade; 
this pathway mainly functions to amplify the cascade and would thus not 
initiate it. This could mean that AD patients that carry the minor CFB allele 
have a more intense complement cascade, and thereby more adverse 
symptoms of the disease (i.e. lower MMSE and higher t-tau). This reasoning 
also lends some support to the model, in which complement activation is one 
of the key events. 
A wide range of methods has been used during the work on this thesis, thus 
approaching a holistic view on the subject. The downside of this, however, is 
that it limits the depth of the investigation. My primary interest has been 
disease mechanisms and pathogenesis, a subject that is often researched by 
use of animal models. I have mostly studied human subjects, however. This 
is of major importance since only humans develop AD. Regrettably, our 
material was somewhat heterogeneous with respect to age between the 
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diagnostic groups; on the other hand we have used a well characterised 
material so the diagnoses are quite certain 
5.3 Final speculations on AD pathogenesis 
The proposed sequence of events leading to AD could explain how people 
get sick, but not why. The initial piece of the puzzle, the ultimate explanation, 
is still missing in the proposed model. 
A common conception is that given enough time everyone will develop AD. 
Although not proven for a fact, this notion has something to it. The question 
should perhaps not be if a person will develop AD; rather, the right question 
would be when. Aging is the major risk factor for AD. I will argue that 
genetics set the stage, and that over time the brain will do the rest. The neural 
network of the brain is a complex system. As such it potentially ends up in an 
attractor. Perhaps dementia is an inevitable point-attractor, and our brains 
have evolved to handle just so many iterations, i.e. the passing of information 
through the system. The system constantly changes in response to the input it 
receives, with synapses growing stronger and weaker, but perhaps, given 
enough time, many synapses will have become so strong that they are no 
longer significantly weakened, with a non-plastic network as a result. This 
notion is supported by findings showing that senescent rats have larger 
unitary EPSPs, as well as a lowered threshold for LTD and a partially 
impaired LTP (Burke and Barnes 2010). Aβ is released in a stimulus 
dependent manner (Cirrito et al. 2005), and it might be that very strong 
synapses release more Aβ, thus dooming the surrounding synapses, and 
thereby eventually dooming themselves. In this context it is interesting to 
note that APOE ε4 transgenic mice show a loss of synapses with aging, and 
that this is accompanied with larger synapses (Cambon et al. 2000). 
Genetic background would predispose different individuals to different ages 
of onset. APOE genotype, for instance, is associated with age of onset 
(Corder et al. 1993; Kurz et al. 1996; Poirier et al. 1993). A simple life 
without intellectual challenges would also be a risk factor, since exposing the 
network to the same kind of input over and over again, with little variation 
would bring it to a non-plastic state much faster. Indeed, participation in 
cognitively stimulating activities is associated with decreased risk of AD 
(Wilson et al. 2002). In terms of the “point-attractor hypothesis” sketched 
above, genetic background and types of input would determine the number of 
iterations the neuronal network of an individual can withstand. 
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Probably the setup of genes of a person, should also be regarded as a complex 
system, meaning that the relation between susceptibility genes and risk is not 
linear, and that clinical symptoms should be regarded as emergent properties 
of this complex system (Khachaturian 2000). Perhaps more or less specific 
combinations of genes work in synergy, though in different ways, 
nevertheless producing the same or at least similar outcome. In genetic 
studies of AD we look for alleles that increase or decrease the risk for the 
disease by comparing AD subjects with normal controls. Perhaps this is not 
an optimal approach. AD is a relatively common disease, and some say that 
eventually everyone will get it. Could it be that we fail to detect the SAD 
causing genes because they are too common, and thus get lost in a sort of 
genetic noise? This is a conceivable scenario if these genes do indeed work in 
synergy, by themselves posing a very small risk, but in specific clusters 
causing a great risk. This highlights the level on which future genetic 
association studies should be made, and also the importance of control 
subjects. Some people grow very old without developing dementia. Although 
it seems as if Aβ is sufficient to initiate the events leading to AD, non-
demented elderly people can have substantial plaque pathology (Bennett et al. 
2006; White 2009; O'Brien et al. 2009; Iacono et al. 2009). Something is 
clearly missing in our understanding of AD - perhaps these extraordinary 
non-demented people should be more extensively studied? 
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6 CONCLUSIONS 
I. In paper I we identified AGER, the gene encoding 
RAGE, as a probable susceptibility gene for SAD. 
II. In paper II we show that the key complement protein C3 
is involved in elimination of synapses in the 
hippocampus of mice, and that the subsequent increase 
of synapses that follow deletion of C3 is partially 
compensated by a reduced release probability in 
glutamate synapses. 
III. In paper III we concluded that C3, C4 and CR1 are not 
suitable as CSF biomarkers for AD. There was, 
however, a trend towards increased levels of these 
proteins in AD, and we interpret this trend as support for 
the hypothesis of complement involvement in AD 
pathogenesis. 
IV. In the final paper of this thesis we concluded that there 
was no association of C2/CFB, C3 or CR1 with AD in 
the investigated population. This does not mean that no 
such association exists; it should rather be interpreted as 
if the association exists, the effect size is very small. 
Finally, we concluded that there was an association of 
C2/CFB with MMSE and high tau levels in AD patients. 
Thus, in the present thesis I have presented evidence in favour of viewing 
AD as a disease primarily affecting synapses. 
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7 FUTURE PERSPECTIVES 
Most scientific work increases our knowledge about the world, but perhaps 
even more it makes us realise the limitations of our knowledge. The work 
presented here is not different as it awakes at least as many questions as it 
provides answers for. Below I will suggest some potential future directions 
for those with interest and recourses. 
In paper I we identify an increased risk for AD in subjects with the 82S 
variant of RAGE. We speculate that the 82S variant of RAGE might be more 
effective in mediating the LTP-inhibiting action of Aβ. This could be tested 
by constructing transgenic mice that carry this variant only and evaluate how 
they respond to Aβ. Additional gene association studies could also be made 
to further tie the LTP-inhibiting effect of Aβ seen in animal studies to actual 
AD patients. Interesting candidate genes would be those encoding key LTP 
proteins, e.g. the NMDAR, protein kinase C, CAMK II. 
 In paper II we show that C3 is involved in elimination of synapses in 
the hippocampus of mice. The natural course of direction here, would be to 
directly investigate the involvement of the complement system in AD 
pathophysiology, e.g. if C3 KO mice are protected from Aβ-induced synapse 
elimination. Constructing a double transgenic mouse, deficient in C3, and 
carrying human APP with a FAD mutation would be a promising approach. 
 Although we concluded that none of the investigated complement 
proteins were suitable CSF biomarkers for AD in paper III, the CSF levels of 
several complement proteins remain unknown. A thorough investigation of 
complement levels, including the activation products, is definitely warranted. 
 In paper IV we failed to detect any associations of the investigated 
complement genes, most likely due to the small effect size of most 
susceptibility genes for SAD. An interesting question is how many risk 
alleles a person can have, but not develop AD. Are the risks additive or do 
they work in synergy? Perhaps different forms of AD can be distinguished by 
specific sets of susceptibility genes. To test this holistic hypothesis a very 
large material would be necessary, since most susceptibility genes are quite 
uncommon. A way to reduce the sample size, however, would perhaps be to 
only include patients with known family history. 
Be that as it may, the answer to the puzzle of AD will most likely be 
centred on synaptic function, and include the terms age and genetics. 
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